Navigation Links
Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
Date:3/23/2009

ebo-controlled trial. Morphotek expects to enroll up to 900 subjects in this clinical study that will be conducted globally at sites in North America, South America, Europe, Australia and Asia.

"Ovarian cancer is a disease that is devastating to the lives of patients and caregivers," said Nicholas Nicolaides, Ph.D., President and Chief Executive Officer at Morphotek. "The agreement reached in the SPA process for farletuzumab's Phase III trial may bring us one step closer to providing hope in their lives and further exemplifies our human health care (hhc) mission to bring treatments to the people who need them most."

Farletuzumab is a monoclonal antibody that binds to and blocks the function of folate receptor alpha (FRA), a cell surface protein on tumor cells that confers a growth advantage to tumorigenic cells in vitro. FRA has been demonstrated by several independent studies to be expressed on ovarian cancer cells. Preclinical data support the theory that farletuzumab achieves its pharmacological effect by two mechanisms: first, by the capacity of farletuzumab to block signaling inside cancer cells and, second, by stimulating the patient's immune system to attack and destroy the FRA positive-tumor cells. The pre-cursor to farletuzumab was originally developed by Dr. Lloyd Old at the Ludwig Institute for Cancer Research applying his pioneering work that employed whole cell immunization of tumors to identify cell surface factors. These efforts led to the development of a panel of novel antibodies that can recognize tumor cell surface antigens as well as tumor stromal cell surface antigens. Morphotek licensed the antibody and improved it using the company's proprietary morphogenics technology.

Ovarian cancer, which ranks fifth as the cause of cancer deaths in women, usually grows asymptomatically before it is discovered. The National Cancer Institute estimates that there were 21,650 new cases of ovarian
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
2. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
3. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
4. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
5. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
6. Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
7. Eisai Inc. and the North American Thrombosis Forum (NATF)* Introduce the DVTeamCare(TM) Hospital Award and Call for Nominations
8. Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)
9. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
10. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... UK (PRWEB) May 04, 2015 During ... witness a 7.7% CAGR. Currently, the European and APAC ... world, while the North American probiotic market lags behind ... local population. , The North American probiotic market ... over 58%), followed by Canada and Mexico. The North ...
(Date:5/4/2015)... Kansas City, MO (PRWEB) May 04, 2015 ... senior vice president and chief physician executive, and William ... officer, have received and accepted personal invitations from the ... annual National Security Forum (NSF) at the Air War ... NSF is to expose influential citizens to senior U.S. ...
(Date:5/4/2015)... Georgia (PRWEB) May 04, 2015 Each year, ... country to raise funds and awareness for breast cancer. This ... Surgery will be featured as the entertainment sponsor for the ... Cure” on May 9 at the Lenox Square Mall. , ... Atlanta race, and to raise $1.2 million. Perimeter Plastic Surgery ...
(Date:5/4/2015)... 2015 TROY Healthcare Solutions is proud ... Regional User Group (RUG) Conference in Baltimore, MD from ... Regional User Group provides an opportunity for clients to ... exhibitor gallery. , In addition to sponsoring the event, ... North Atlantic RUG Conference. Attendees can stop by the ...
(Date:5/4/2015)... Angeles, CA (PRWEB) May 04, 2015 In ... Ty Smalley took his own life. In the wake of ... for the Silent, an organization that exposes the grim reality ... is also a platform for Kirk and Laura to share ... prevent their tragedy from happening to another family — a ...
Breaking Medicine News(10 mins):Health News:North America Probiotic Market to Increase by 2019, Announces MicroMarketMonitor in Its New Research Report Recently Published at MarketPublishers.com 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3
... least 80 people have died in a cholera outbreak in ... 2,000 others are affected.// Cholera is an infectious disease that ... sent medical teams to deal with the crisis while it ... Buba Umar, of the state ministry of health told the ...
... Some of the cosmetic products one uses in every ... scientists say could cause cancers, hormone problems and skin ... different chemicals to her body in the form of ... Mail. ,Most beauty products contain chemicals linked ...
... The Food and Drug administration (FDA) has asked a panel ... fillings due to the persistent complaints that the fillings may ... evidence to suggest that the fillings were dangerous in dozen ... the silver fillings, and the FDA has asked the panel ...
... term illnesses like Parkinson's and heart disease will soon ... ,Proposals have been made to train some ''expert ... patients' medical conditions and management of their drugs, from ... hold their own specialist clinics for patients with life-threatening ...
... to experts at the World Congress of Cardiology, a ... This ‘polypill’ could save lives of millions of people//especially ... ,Aspirin, statins and ACE inhibitors are the three ... other cardiovascular health problems are known to be prevented ...
... A report has indicated that the efficacy of childhood vaccines ... //popularly used in the industry- example pollutant polychlorinated biphenyls (PCBs) ... investigated the response to vaccination in two companions from the ... was measured by examining the blood sample from the mother ...
Cached Medicine News:Health News:Pharmacists to take over Treatment of Long-Term Illnesses 2Health News:Pharmacists to take over Treatment of Long-Term Illnesses 3Health News:“Polypill”- to prevent recurrent heart diseas 2
(Date:5/4/2015)... TORONTO , May 4, 2015 ... that it intends to dividend to its stockholders a ... a definitive licensing agreement to license its RapidMist™ buccal ... (OTCQB:SMFI). As announced on April 23, 2015, ... respect of the licensing of its RapidMist™ buccal drug ...
(Date:5/4/2015)... 4, 2015 Rogne Bioscience, a privately-held biotechnology ... that preclinical and mechanism of action data will be ... Investigative Dermatology (SID) Annual Meeting being held May 6-9, ... Georgia . Logo - http://photos.prnewswire.com/prnh/20150501/213318LOGO ... RON2315, a novel, low MW (<1700 daltons) peptide as ...
(Date:5/4/2015)... 4, 2015   HeartWare International, Inc . (NASDAQ: ... support technologies that are revolutionizing the treatment of advanced heart ... , is scheduled to present at the Bank of America ... Vegas on Thursday, May 14, 2015, at 10:00 ... of the Company,s presentation at the conference will be available ...
Breaking Medicine Technology:Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2
... Colo., May 13, 2011 Mesa Laboratories, Inc. (NASDAQ: ... of Directors has declared a regular quarterly cash dividend ... on June 15, 2011 to shareholders of record at ... Mesa Laboratories develops, acquires, manufactures and markets electronic ...
... Spine, a medical device company that designs, develops, manufactures ... disorders, today announced that the Company presented an overview ... the 6th Annual Spine Technology Summit, hosted by P&M ... California. "Life Spine has an extremely active ...
Cached Medicine Technology:
BD Vacutainer® Specialty Tubes - Other - Glass...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
The Erythrocyte Sedimentation Rate (ESR) can be used as a nonspecific search technique in case of suspicion of inflammatory reactions as well as for judgement of their development. VACUETTE® ESR...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
Medicine Products: